Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
13.61
-0.70 (-4.89%)
At close: Nov 13, 2026, 4:00 PM EST
13.68
+0.07 (0.51%)
After-hours: Nov 13, 2026, 7:30 PM EST
Korro Bio Revenue
Korro Bio had revenue of $1.29M in the twelve months ending September 30, 2026, down -82.47% year-over-year. In the year 2025, Korro Bio had annual revenue of $6.39M with 181.46% growth. That makes Korro Bio the 43,194th largest company in the world by revenue and 5,976th in the United States.
Revenue (ttm)
$1.29M
Revenue Growth
-82.47%
P/S Ratio
144.59
Revenue / Employee
$22,276
Employees
58
Market Cap
186.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.39M | 4.12M | 181.46% |
| Dec 31, 2024 | 2.27M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 75.93M |
| Keros Therapeutics | 40.76M |
| ProQR Therapeutics | 21.05M |
| Pyxis Oncology | 11.04M |
| Entrada Therapeutics | 3.98M |
| Cartesian Therapeutics | 1.03M |
| Palisade Bio | 500.00K |
| Artiva Biotherapeutics | 251.00K |
KRRO News
- 1 day ago - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Korro to Present at the 2026 Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 9 days ago - Korro Bio Inc trading resumes - TheFly
- 9 days ago - Korro Bio Inc trading halted, volatility trading pause - TheFly
- 9 days ago - Korro Bio reports Q3 EPS (98c), consensus ($1.26) - TheFly
- 9 days ago - Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Korro Bio Quarterly report: Q3 2026 - Filings
- 9 days ago - Korro Bio Earnings release: Q3 2026 - Filings